Table 5.

Summary of Meta-Analysis Results of Individual Outcomes According To Gestational Age At Randomization And Indication For Treatment.

GA (wks)	Outcome	No. studies	No. infants	No. infants exposed to Magnesium n (%)	No. infants exposed to placebo n (%)	RR	95% CI
< 32–34	Combined death or CP	5	5225	2589 (49.6)	2636 (50.4)	0.92	0.83–1.03
	CP	5	5225	2589 (49.6)	2636 (50.4)	0.70	0.55–0.89
	Death	5	5235	2594 (49.6)	2641 (50.4)	1.01	0.89–1.14
	Moderate-severe CP	3	4250	2096 (49.3)	2154 (50.7)	0.60	0.43–0.84
	Death or moderate-severe CP	3	4250	2096 (49.3)	2154 (50.7)	0.85	0.73–0.99
< 30	Combined death or CP	3	3107	1522 (49.0)	1585 (51.0)	0.91	0.81–1.03
	CP	3	3107	1522 (49.0)	1585 (51.0)	0.69	0.52–0.92
	Death	3	3107	1522 (49.0)	1585 (51.0)	1.00	0.87–1.15
	Moderate-severe CP	2	2820	1378 (48.9)	1442 (51.1)	0.54	0.36–0.80
	Death or moderate-severe CP	2	2820	1378 (48.9)	1442 (51.1)	0.84	0.71–0.99
“Neuroprotection” trials only
Combined death or CP		4	4314	2130 (49.4)	2184 (50.6)	0.86	0.75–0.99
CP		4	4314	2130 (49.4)	2184 (50.6)	0.71	0.55–0.91
Death		4	4324	2135 (49.4)	2189 (50.6)	0.95	0.80–1.13
Moderate-severe CP		3	4250	2096 (49.3)	2154 (50.7)	0.60	0.43–0.84
Death or moderate-severe CP		3	4250	2096 (49.3)	2154 (50.7)	0.85	0.73–0.99